Prognostic Performance of Pancreatic Stone Protein in Critically Ill Patients with Sepsis

Abstract

<b>Aim:</b> To assess the prognostic value for 28-day mortality of PSP in critically ill patients with sepsis. <b>Material & methods:</b> 122 consecutive patients with sepsis were enrolled in this study. Blood samples were collected on admission and day 2. <b>Results:</b> On admission, the combination of PSP and lactate achieved an area under the receiver operating characteristic (AUC-ROC) of 0.796, similar to sequential organ failure assessment score alone (AUC-ROC: 0.826). On day 2, PSP was the biomarker with the highest performance (AUC-ROC: 0.844), although lower (p = 0.041) than sequential organ failure assessment score (AUC-ROC: 0.923). <b>Conclusion:</b> The combination of PSP and lactate and PSP alone, on day 2, have a good performance for prognosis of 28-day mortality and could help to identify patients who may benefit most from tailored intensive care unit management.